Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | A call to review the CMS national coverage determination of anti-amyloid antibodies

Rebecca Edelmayer, PhD, Alzheimer’s Association, highlights the access issues surrounding anti-amyloid therapies for Alzheimer’s disease (AD) as a matter of concern. The Centers for Medicare and Medicaid Services (CMS) have implemented a policy that is currently hindering Medicare access to FDA-approved AD treatments. Despite the FDA granting accelerated approval to aducanumab and lecanemab, patients are unable to access these medicines outside of a clinical trial. The CMS continue to review new evidence and will modify the national coverage determination if deemed appropriate. In a recent statement, the Alzheimer’s Association have called for an urgent reversal of this policy, so that Medicare beneficiaries with Alzheimer’s disease get the same coverage afforded to those with other fatal diseases.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Edelmayer is a full time employee of the Alzheimer’s Association.